Citations

Clear

1526 citation(s) found for "Sun, Yu".

Randomized phase III study of nivolumab after surgery and adjuvant chemotherapy in NSCLC (ECOG-ACRIN EA5142, ALCHEMIST).
Sun, Zhuoxin, Rudin, Charles M., Simone, Charles B., Oettel, Kurt R., Kozono, David E., Sands, Jacob, Heymach, J, Raez, Luis E., Malik, Shakun , Stinchcombe, Tom, Mandrekar, Sumithra J. , Vokes, Everett E., Gandara, David R., Staley, Charles A., Ramalingam, Suresh S., Khullar, Onkar, Chaft, Jamie E. , Rudin, Charles M. , Simone, Charles B. , Kozono, David , Govindan, Ramaswamy , Sands, Jacob , Heymach, John V. , Raez, Luis , Stinchcombe, Thomas E. , Gerber, David E. , Bradley, Jeffrey D. , Vokes, Everett E. , Gandara, David R. , Ramalingam, Suresh S. , Khullar, Onkar V.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 8000-8000

10.1200/jco.2026.44.16_suppl.8000 Get It

8000 Background: The NCI’s ALCHEMIST program has screened thousands of patients with resected lung adenocarcinoma for mutations in EGFR and ALK. EA5142 studied the efficacy of adjuvant nivolumab after standard of care adjuvant therapy in patients with resected lung adenocarcinoma without sensitizing EGFR and ALK alterations and squamous cell carcinoma. Methods: Patients enrolled in the ALCHEMIST screening trial (A151216) with resected NSCLC tumors at least 4 cm and/or lymph node positive (N1/2) (for lung adenocarcinoma, without sensitizing EGFR and ALK alterations), were centrally tested for tumor cell PD-L1 expression using the DAKO 28-8 clone. After completion of all planned adjuvant therapy (chemotherapy and/or post-operative radiation) patients were randomized 1:1 to adjuvant nivolumab 480 mg IV every 4 weeks for up to 1 year or best supportive care. Patients were stratified by tumor histology, stage (AJCC 7 th edition IB/IIA vs IIB/IIIA), prior adjuvant treatment, and PD-L1 status (<1% vs ≥1%). The primary study endpoints were disease free survival (DFS) in all patients and in patients with high tumor PD-L1 expression (≥50%). Overall survival was powered to be tested hierarchically, if DFS was positive. Results: Between July 2016 and October 2019, 935 patients were randomized across 378 sites. The treatment arms were balanced for age (median 66 years), sex (52% male), smoking status (10% never smoked), histology (29% squamous), stage and PD-L1 expression (29% PD-L1 high). With a median follow-up of 72.6 months, nivolumab did not improve DFS in the intention to treat population (median DFS 71.3 months vs. 68.8 months in observation arm), hazard ratio (HR) 0.97 (95% CI 0.81-1.17, p=0.78) or the PD-L1 ≥50% subset (median DFS 89.8 months vs. 78.5 months in observation arm), HR 0.86 (95% CI 0.59-1.25, p=0.43). In multivariate analysis, adjusting for age, gender, and smoking history, the DFS HR was 0.99 (95% CI 0.82-1.19, p=0.89) in all randomized patients and 0.82 (95% CI 0.56-1.2, p=0.31) in the PD-L1 ≥50% subset. As the primary recurrence endpoint included any lung cancer, including new primaries, a sensitivity analysis was performed excluding new primary lung cancers, DFS HR 0.97 (95% CI 0.80-1.18, p=0.76) in all patients and HR 0.88 (95% CI 0.60-1.30, p=0.52 in the ≥50% subset. The median duration of treatment with adjuvant nivolumab was 9.4 months (range 0-12.7 months). The most common reasons for nivolumab discontinuation were adverse event (29%), patient withdrawal (11%), and disease progression while on treatment (10%). Treatment related grade 3-5 toxicities were reported in 25% of patients: Grade 3: 23%, Grade 4: 2%, Grade 5: <1%. Conclusions: In patients with resected NSCLC (≥4cm or LN+, EGFR/ALK -) adjuvant nivolumab did not improve DFS, irrespective of tumor PD-L1 expression. Clinical trial information: NCT02595944 .
Safety and reliability of isatuximab subcutaneous on-body injector: Results across the phase 3 IRAKLIA, phase 2 IZALCO and phase 1b TCD15484 trials.
Leleu, Xavier P., Cerchione, Claudio, Ailawadhi, Sikander, Minarik, Jiri, Špička, Ivan, Rocafiguera, Albert Oriol, Ocio, Enrique M., LeBlanc, Richard, Parmar, Gurdeep , Yañez, Eduardo, Cao, Carmen, Rojas, Christine , Xia, Zhong-Jun, Wang, Y L , Khan, Umer, Stefanova-Urena, Maya, Suzan, Florence, Moreau, Philippe, Quach, H, Leleu, Xavier , Cerchione, Claudio , Ailawadhi, Sikander , Minařík, Jiří , Špička, Ivan, Ocio, Enrique M. , LeBlanc, Richard , Xia, Zhong-Jun, Moreau, Philippe , Quach, Hang

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 7563-7563

10.1200/jco.2026.44.16_suppl.7563 Get It

7563 Background: Subcutaneous (SC) drug delivery options have become more widely available in multiple myeloma (MM). SC delivery of isatuximab (Isa), an anti-CD38 monoclonal antibody, has been investigated across clinical trials via a novel hands-free on-body injector (OBI). Isa SC OBI features a small, retractable needle, establishing the first device-enabled delivery of an oncologic treatment. The Phase 3 IRAKLIA, Phase 2 IZALCO, and Phase 1b (TCD15484) trials consistently demonstrated similar efficacy and safety of Isa SC OBI vs Isa IV in relapsed/refractory MM (RRMM) patients (pts). Here, we present a cross-trial analysis exploring safety and reliability of Isa SC OBI in RRMM pts. Methods: Pts with RRMM in IRAKLIA (N=263) and the Phase 1b expansion cohort (N=22) received 1400 mg Isa SC OBI plus pomalidomide and dexamethasone (d). In IZALCO, RRMM pts (N=64) received 1400 mg Isa SC OBI + carfilzomib (K)-d. Pts were monitored for 4 hrs (IRAKLIA) or 1-2 hrs (IZALCO) following first administration and for 1 hr for the following cycle (C) 1 administrations to assess local tolerability. Pre-infusion medications included montelukast (C1), steroids, acetaminophen and H1 antihistamines. Pts without systemic infusion-related reactions (IRRs) after 4 consecutive administrations of Isa SC OBI had subsequent pre-medication reassessed at investigator’s discretion. Safety and device performance explored in this cross-trial analysis of company sponsored studies were assessed in the Isa SC OBI cohorts by the duration of injection, IRRs, local injection-site reactions (ISRs), and injection/device success, which were defined similarly across all trials. Results: The median duration of Isa SC OBI injection was 13 mins in IRAKLIA, 12 mins in IZALCO, and 10 mins in the Phase 1b trial (6426 total injections, N=349 pts). IRRs across trials occurred in 6/6426 (0.09%) injections and 4/349 (1.15%) pts. IRRs were mostly grade 1 (G; 3/6426, 0.05%) with 1 G3 (0.02%); none leading to discontinuation. In IRAKLIA, 80/263 (30.4%) pts did not require premedication (931/5145 injections, 18.1%); no IRRs occurred in this group. Across trials, ISRs occurred in 21/349 (6.02%) pts resulting in 35 (0.54%) ISR events. Most ISRs were G1 (33, 0.51%), the remaining were G2 (2, 0.03%) and generally occurred on the day of injection. 99.9% (6421/6426) of injections in 98.6% (344/349) pts were successful (completed without interruption) across all trials. Conclusions: These findings support overall low, self-limiting rates of IRRs and ISRs across trials, with >6000 (99.9%) Isa SC OBI injections successfully delivered. Isa SC OBI shows reproducible safety and reliability in IRAKLIA, IZALCO and Phase 1b trials, supporting it as a novel administration option for MM pts and its potential for future exploration in at-home administration. Clinical trial information: NCT04045795 , NCT05405166 , and NCT05704049 .
Immune effector cell–associated enterocolitis (IEC-EC) incidence and characterization in cilta-cel–treated patients with RRMM in CARTITUDE clinical studies.
Lin, Yi, Tian, Shaozhou K. , Montgomery, Elizabeth, Roeloffzen, W, Jin, Jie, Sun, Huabin, Plaks, Vicki , Li, Katherine , Jablow, Lee, Sharma, Mukta, Singh, Preeti, Patel, Nitin , Lee, Erin, Sharma, Bhawna, Anguille, S, Minnema, Monique, Montgomery, Elizabeth Anne , Khan, Abdullah , Rocchi, Serena , Zamagni, Elena , Jin, Jie , Lee, Erin, Anguille, Sébastien , Minnema, Monique C , Strouse, Christopher

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 7533-7533

10.1200/jco.2026.44.16_suppl.7533 Get It

7533 Background: Ciltacabtagene autoleucel (cilta-cel) shows benefit for patients (pts) with relapsed/refractory multiple myeloma (RRMM). A recently recognized uncommon adverse reaction, IEC-EC is characterized by severe/persistent diarrhea typically 1–3 months post CAR-T cell infusion. Here we summarize incidence and features of IEC-EC in clinical trials of cilta-cel for RRMM. Methods: 483 pts across RRMM studies (CARTITUDE-1, -2, -4, and CARTIFAN-1) were evaluated for evidence of IEC-EC. The clinical picture and nomenclature for IEC-EC were described in the real-world setting after infusion of most pts. As such, retrospective analysis was performed to identify cases consistent with IEC-EC, defined as prolonged (≥3 weeks) and severe (≥grade 3) diarrhea after cilta-cel infusion, without clear infectious etiology. Correlative biomarker analyses included peripheral CAR-T cell expansion/persistence, immune cell composition, and cytokines/inflammatory markers. Centralized pathomorphological review and immunohistochemical analysis of available biopsies was conducted. Results: Across RRMM studies, 6/483 (1.2%) pts demonstrated the clinical picture of IEC-EC, presenting 12–214 days after receiving cilta-cel (median onset 67 days post infusion). Best response was CR/sCR for all subjects. Pts received therapies including steroids (4/6). Four pts experienced symptom resolution within 123–227 days; 2 had persistent symptoms until death (causes: multiorgan failure and COVID19). Pts with IEC-EC had lower levels of B cells and higher levels of CAR+ T cells and inflammatory cytokines (eg, IL-6) at onset compared to a GI symptom-free control group at comparable time; while all cilta-cel–treated pts experienced B cell depletion, pts with IEC-EC had more prolonged deficiency. Histological analyses of GI biopsies from 5 pts with IEC-EC revealed plasma cells, normally present in the GI tract, were absent. CAR-T cells were detected and localized to the lamina propria and were not observed juxtaposed with epithelia, making it unlikely direct damage to epithelia was caused by CAR-T cells. Histologic damage was greater in the small intestine (predominantly duodenum) than the colon. Conclusions: Retrospective analysis of cilta-cel trials identified a low IEC-EC incidence (1.2%). Findings support a reactive mechanism involving plasma cell depletion and immune dysregulation rather than direct CAR-T cell cytotoxicity and highlight the importance of upper endoscopy to identify injury patterns in the small intestine that may be less pronounced in the colon. Although the pathophysiology is not fully defined, increased awareness and earlier diagnosis may improve understanding of management and enhance likelihood of IEC-EC reversibility.
Performance of ChatGPT in generating patient-facing cancer survivorship care plans.
Du, Kaili , Zhang, Yuting, Pradhan, Kristina, Sun, Chenyu

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 1673-1673

10.1200/jco.2026.44.16_suppl.1673 Get It

1673 Background: Survivorship care plans (SCPs) summarize cancer treatments and provide evidence-based recommendations for surveillance, screening, and management of treatment-related complications. Despite the availability of guidelines and templates, SCPs remain underutilized in routine practice due to the time-intensive and error-prone nature of manual creation. Empowering cancer survivors to use publicly available large language models (LLM)–based chatbots, such as ChatGPT, may offer a feasible solution to this problem. Methods: Standardized patient profiles were developed for six common cancers: breast, colorectal, non–small cell lung, small cell lung, prostate cancer, and diffuse large B-cell lymphoma. Profiles were reviewed by a primary care physician and an oncologist to ensure clinical accuracy and representativeness of common survivorship scenarios. Using lay language to simulate real-world patient input, ChatGPT (version 5.2, publicly available at the time of the study) was prompted with each profile using the question, “What follow-up care do I need?” Common survivorship symptoms for each cancer were also tested. Responses were evaluated across five domains: medical accuracy (concordance with current ASCO or NCCN guidelines), thoroughness, patient safety and risk framing, clarity and patient comprehension, and actionability. Five-point Likert scales were used (1 = not at all; 5 = very much). Scores were averaged across two independent physician raters. Readability was assessed using the Flesch Reading Ease Score. Results: ChatGPT-generated SCPs demonstrated high medical accuracy (mean score 4.25/5), with no factual errors or hallucinations identified on manual review. Patient safety and risk framing scored 3.75/5; symptom red flags and care escalation guidance were appropriately stated in most scenarios. Thoroughness was moderate (3.50/5), with key survivorship elements, such as smoking cessation counseling or genetic risk considerations; sometimes omitted unless explicitly prompted. Readability was limited, with a mean Flesch Reading Ease Score of 40.5, corresponding to a college reading level and exceeding recommended readability standards for patient education materials. Clarity (3.38/5) and actionability (3.38/5) were similarly constrained due to dense medical language. Conclusions: ChatGPT demonstrated high medical accuracy in generating survivorship care plans across six common cancers, supporting the feasibility of using publicly available LLMs to guide survivorship care. However, improvements in comprehensiveness, readability, and patient-centered actionability are necessary before such tools can be safely integrated into clinical survivorship workflows.
Potential BMI-dependent overall survival differences in postmenopausal breast cancer patients treated with CDK4/6 inhibitors: A Mayo Clinic platform study.
Sun, Chenyu, Billstein, Laura , Zhang, Julie Ying, Fickel, Abigail, Liu, Li , Du, Kaili , Lees, Elizabeth , Sun, Chenyu, Han, Yiqun , Zhang, Julie Ying

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 1110-1110

10.1200/jco.2026.44.16_suppl.1110 Get It

1110 Background: CDK4/6 inhibitors with endocrine therapy are widely used for HR+/HER2– metastatic breast cancer (BC). While studies have shown similar progression-free outcomes across agents, overall survival (OS) data are limited. Since OS is a definitive endpoint and BMI may influence outcomes, this study examines BMI-dependent OS differences among CDK4/6 inhibitors. Methods: A retrospective cohort study was conducted using the Mayo Clinic Platform full AMC1 dataset. Postmenopausal women with BC receiving palbociclib/ribociclib/abemaciclib plus aromatase inhibitor (AI) were included. Patients with prior use of fulvestrant, anthracyclines, radiation therapy, GnRH agonists, or history of MACE, heart failure, myocardial infarction, or stroke before BC diagnosis were excluded. Patients were stratified by BMI and CDK4/6 inhibitor. The primary outcome was 5-year OS. Results: Among 1,989 patients (palbociclib: 868; ribociclib: 465; abemaciclib: 656), palbociclib was associated with significantly worse OS compared to ribociclib in BMI <25 (HR 2.91; 95% CI: 1.76–4.79; P < 0.01) and BMI ≥30 (HR 1.91; 95% CI: 1.21–3.01; P < 0.01). Compared to abemaciclib, palbociclib showed worse OS: BMI <25 (HR 1.73; P < 0.01), BMI 25–30 (HR 1.56; P < 0.01), and BMI ≥30 (HR 1.82; P < 0.01). No significant OS differences were observed between ribociclib and abemaciclib. Palbociclib patients were older, particularly in BMI <25 (Cohen's D = 0.39 vs. ribociclib; 0.27 vs. abemaciclib) and BMI ≥30 (0.28 vs. ribociclib; 0.23 vs. abemaciclib). In the BMI 25–30 group, palbociclib group was also older than ribociclib group (Cohen's D = 0.26). Conclusions: In postmenopausal BC patients on AIs and CDK4/6 inhibitors, palbociclib was associated with worse OS in BMI < 25 and BMI ≥ 30 groups, while ribociclib and abemaciclib showed similar outcomes across BMI groups. Palbociclib patients were older than those on other drugs, which may partially confound results; however, in the BMI 25–30 group, despite similar age differences, no survival difference was observed between palbociclib and ribociclib, suggesting age alone may have limited impact. These findings indicate a potential interaction between BMI and drug choice, and highlight the need for prospective studies to confirm and adjust for these variables. Limitations include the observational design and inability to perform multivariable regression analyses to adjust for confounders. Overall survival comparisons by CDK4/6 inhibitor and BMI subgroup. Comparison BMI Group Hazard Ratio (95% CI) P-value Palbociclib vs Ribociclib <25 2.91 (1.76 – 4.79) < 0.01 25 – 30 1.34 (0.87 – 2.071) 0.17 ≥30 1.91 (1.21 – 3.01) < 0.01 Palbociclib vs Abemaciclib <25 1.73 (1.29 – 2.32) < 0.01 25 – 30 1.56 (1.09 – 2.23) < 0.01 ≥30 1.82 (1.15 – 2.88) < 0.01 Ribociclib vs Abemaciclib <25 1.27 (0.81 – 1.99) 0.29 25 – 30 0.87 (0.54 – 1.43) 0.59 ≥30 1.05 (0.63 – 1.75) 0.85
Differential risk patterns of secondary breast cancer in medullary versus papillary thyroid carcinoma survivors: A SEER-based analysis.
Liu, Li, Billstein, Laura , Vinh, Tuan, Zhang, Julie Ying, Fickel, Abigail, Du, Kaili , Lees, Elizabeth , Sun, Chenyu, Liu, Li, Zhang, Julie Ying, Sun, Chenyu

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 10585-10585

10.1200/jco.2026.44.16_suppl.10585 Get It

10585 Background: Prior studies suggest that thyroid cancer (TC) survivors may have an elevated risk of secondary malignancies. However, whether this risk differs by TC histology, specifically with breast cancer (BC), remains unclear. We aimed to investigate the association between TC subtype—papillary thyroid carcinoma (PTC) versus medullary thyroid carcinoma (MTC)—and subsequent BC risk, adjusting for demographic factors. Methods: We conducted a retrospective cohort study using the SEER (2000–2022), including adults with a primary, microscopically confirmed PTC or MTC. Subsequent BC occurrence was defined as a binary outcome (yes/no). Multivariable logistic regression was used to estimate adjusted odds ratios (aORs) for MTC versus PTC, controlling for age (<50 vs ≥50 years), sex, and race. Stratified analyses by age and race were also performed. Stata 15 was used for statistical analyses. Results: 14,840 patients (14,563 PTC, 277 MTC) were included. MTC patients were older (mean 59.08±12.66 vs 56.16±12.98 years, p<0.001) and had a higher proportion of males (44.4% vs 29.4%, p<0.001). The overall incidence of secondary BC was lower in MTC patients (7.6% vs 22.5%, p<0.001). In unadjusted logistic regression, MTC was associated with significantly lower BC risk (OR=0.28, 95% CI: 0.18–0.44, p<0.001). After adjustment, MTC remained significantly protective (aOR=0.34, 95% CI: 0.22–0.55, p<0.001). Stratified analyses demonstrated consistent findings across age groups (<50: aOR=0.10, 95% CI: 0.03–0.42; ≥50: aOR=0.34, 95% CI: 0.21–0.54), , as well as white and Hispanic patients. Conclusions: Survivors of MTC have a substantially lower risk of developing secondary BC compared to PTC survivors. This association persists after adjustment for age, sex, and race, and is consistent across age and most racial subgroups. However, different BC types were not assessed due to limited number of BC patients among MTC survivors, and the small MTC sample size and potential survival differences between groups may affect the results. These findings highlight a possible effect of TC subtype on BC risk, suggesting the potential influence of underlying biological or genetic mechanisms. Baseline demographic characteristics of patients with papillary and medullary thyroid carcinoma. Characteristic Papillary Thyroid Carcinoma (PTC) (N=14,563) Medullary Thyroid Carcinoma (MTC) (N=277) P-value Age at Diagnosis 0.0002* Mean ± SD, years 56.16 ± 12.98 59.08 ± 12.66 Median, years 57 61 Sex, n (%) <0.001† Female 10,288 (70.6) 154 (55.6) Male 4,275 (29.4) 123 (44.4) Race, n (%) 0.015† White 10,263 (70.5) 197 (71.1) Black 921 (6.3) 15 (5.4) American Indian 77 (0.5) 1 (0.4) Asian 1,379 (9.5) 13 (4.7) Hispanic 1,903 (13.1) 50 (18.1) SD: Standard Deviation. *P-value from two-sample t-test (equal variances assumed). †P-value from chi-square test for the overall distribution across categories.
Editorial: Enhancing sports injury management through medical-engineering innovations
Chen, Lu , Sun, C J , Xu, Penghao, Song, Wei, W, Liu

Mayo Clinic

Frontiers in Sports and Active Living | May 22, 2026 | Volume: 8 | Issue: No issue available | Pages: No page available

10.3389/fspor.2026.1872784 | PMID 42256047 Get It

6PPDQ Exposure Exacerbates Seizure-Induced Neuronal Damage via the TP53/Nrf2 Axis: An Integrated Strategy Combining Network Toxicology and Experimental Validation
Xie, Ruijin , Xiao, Wei, Xu, Hua, Luo, Yufan , Xiao, Xue, Pan, Qiyang, Xu, Shengjie, Liu, Li, Liu, Yueying , Liu, Yueying , Xie, Ruijin , Sun, Chenyu

Mayo Clinic

Toxics | May 19, 2026 | Volume: 14 | Issue: 5 | Pages: 443

10.3390/toxics14050443 | PMID 42198569 Get It

As an emerging tire wear-derived environmental contaminant, 6PPD-quinone (6PPDQ) has raised significant concerns regarding its neurotoxic potential, particularly for children exposed to recycled tire crumb rubber in playgrounds. However, the molecular mechanisms by which 6PPDQ influences neurological disorders such as epilepsy remain poorly understood. In this study, we employed an integrative framework combining network toxicology, bulk analysis of human epileptic brain tissues, Mendelian randomization, and molecular dynamics simulations to elucidate these mechanisms. Our findings, validated through CETSA-WB and SPR, identify 6PPDQ as a direct ligand that binds to and stabilizes neuronal TP53. Through a synergistic double-hit mechanism, 6PPDQ directly engages the TP53 pathway while simultaneously triggering microglial interleukin-6 secretion. These converging pathways lead to the suppression of the master antioxidant regulator Nrf2, resulting in glutathione depletion, excessive reactive oxygen species accumulation, and exacerbated neuronal damage under excitotoxic stress. Experimental validation using glutamate-induced HT22 cell models and microglia–neuron crosstalk systems confirmed that targeting the TP53/Nrf2 axis or scavenging ROS significantly attenuates 6PPDQ-induced neurotoxicity. Our findings highlight critical risks to pediatric neurological health posed by tire-derived contaminants and identify the TP53/Nrf2 axis as a promising therapeutic target. Furthermore, this work provides a robust scientific basis for refining risk assessment frameworks and developing regulatory strategies to mitigate environmental exposure to 6PPDQ.
ER Stress-Mediated Impairment of Hepatic Lipid Export Drives Steatosis in AKI-Induced Remote Liver Injury
Li, Minghua, Ni, Runze, Williams, Kristof , Melaika, Miriame, Sun, Lucas Eli, Fu, Liying, Subramanian, Vijay , Dhanireddy, Kiran, Li, M.X. , Li, Minghua , Fu, Liying, Dhanireddy, Kiran, R, Liu

Mayo Clinic

No container title available | May 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9409706/v1 | PMID 42239770 Get It

Abstract Background Acute kidney injury (AKI) frequently causes remote organ injury including hepatic steatosis, yet whether lipid accumulation reflects increased synthesis or impaired clearance has not been resolved. Methods We used a murine ischemia-reperfusion AKI model. Unbiased liver proteomics was performed at 24 hours after reperfusion, and dysregulated pathways were identified by Gene Set Enrichment Analysis. Results were validated by Western blotting, qPCR, and immunohistochemistry. These findings were complemented by retrospective analysis of two ICU databases (MIMIC-IV and eICU-CRD). Results AKI significantly increased serum ALT and AST and induced hepatic lipid accumulation. Proteomic analysis revealed that key lipogenic enzymes (Scd1, Fasn, Acly, Acaca) were uniformly suppressed rather than upregulated. Proteins essential for VLDL assembly (ApoB, MTTP, ApoE) were significantly downregulated. Plasma triglycerides were decreased while liver triglycerides were increased, consistent with impaired hepatic lipid export. As in renal tubular cells, AKI also disrupted ER protein folding homeostasis in the liver, triggering ER stress. This was evidenced by upregulated levels of the ER chaperone GRP78, increased XBP1 splicing indicative of UPR activation, and elevated expression of the ER stress-induced pro-apoptotic transcription factor CHOP, suggesting that prolonged ER stress may also promote hepatocyte cell death. TLR4/MyD88 signaling was activated, yet inflammatory cytokines were paradoxically reduced, accompanied by Kupffer cell depletion (decreased F4/80) and monocyte infiltration (increased CD68). In 6,996 propensity-matched ICU patients (MIMIC-IV), AKI independently increased the risk of clinically significant liver injury 4-fold (adjusted OR = 4.41). Analysis of 22,727 patients across 208 hospitals (eICU-CRD) identified a lipid dissociation pattern: elevated triglycerides alongside decreased total cholesterol, HDL, and LDL, with dose-dependent scaling across KDIGO stages. Conclusions These data support ER stress-mediated impairment of VLDL export as a primary driver of AKI-induced hepatic steatosis. Clinical validation across two independent ICU databases identifies a dual metabolic insult: enhanced peripheral lipid delivery compounds impaired hepatic export, amplifying hepatic lipid retention. ER stress and lipid export machinery represent potential therapeutic targets for AKI-associated liver injury.
Cognitive dispersion profiles and prediction of cognitive change in early‐onset dementias: Results from LEADS
Hammers, Dustin B., Foster, Elodie, Eloyan, Ani, Thangarajah, Maryanne, Taurone, Alexander, Touroutoglou, Alexandra, Joie, Renaud La, Beckett, Laurel, Gao, Sujuan, Vemuri, Prashanthi, Nudelman, Kelly N., Kirby, Kala, Dage, Jeffrey L., Aisen, Paul, Atri, Alireza, Clark, David G., Day, Gregory S., Duara, Ranjan, Graff‐Radford, Neill R., Grant, Ian, Honig, Lawrence S., Johnson, Erik C. B., Jones, David T., Masdeu, Joseph C., Mendez, Mario F., Parand, Leila, Womack, Kyle, Musiek, Erik, Onyike, Chiadi U., Riddle, Meghan, Rogalski, Emily, Salloway, Stephen, Sha, Sharon J., Turner, Raymond Scott, Wingo, Thomas S., Wolk, David A., Dickerson, Bradford C., Rabinovici, Gil D., Carrillo, Maria C., Apostolova, Liana G., Joie, Renaud La , La Joie, Renaud , Hammers, Dustin B , Eloyan, Ani , Thangarajah, Maryanne, Taurone, Alexander, Touroutoglou, Alexandra , Beckett, Laurel , Gao, Sujuan , Vemuri, Prashanthi , Nudelman, Kelly , Kirby, Kala, Dage, Jeffrey L. , Aisen, Paul , Atri, Alireza , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Honig, Lawrence S. , Johnson, Erik C. B. , Jones, David T. , Masdeu, Joseph C , Mendez, Mario F. , Womack, Kyle , Musiek, Erik , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Stephen, Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S , Wolk, David A. , Dickerson, Bradford Clark , Rabinovici, Gil D. , Carrillo, María C. , Apostolova, Liana G.

Mayo Clinic

Alzheimer's & Dementia | May 19, 2026 | Volume: 22 | Issue: 5 | Pages: No page available

10.1002/alz.71492 | PMID 42151732 Get It

Abstract INTRODUCTION Research into cognitive dispersion – a cognitive process score measuring the intra‐individual variability (IIV) across a single testing session – suggests utility in neurodegenerative populations. Given widespread deficits observed in sporadic early‐onset Alzheimer's disease (EOAD), however, it is unclear if examining cognitive dispersion shows benefit in this condition. METHODS A total of 309 participants (188 amyloid‐positive EOAD, 43 amyloid‐negative early‐onset dementia [EOnonAD], 78 cognitively normal [CN]) completed neuropsychological testing twice over 12 months. Dispersion‐related differences among groups were assessed, as was cognitive dispersion's capacity to predict domain‐specific cognitive trajectories, and its convergence with imaging biomarkers. RESULTS EOAD participants displayed higher cognitive dispersion than EOnonAD participants, and associations with EOAD‐specific biomarkers. Additionally, cognitive dispersion was associated with 12‐month reliable change across several cognitive domains. DISCUSSION These preliminary results examine cognitive dispersion in sporadic EOAD. When used with baseline cognitive performance, cognitive dispersion measures may enrich future clinical trials in EOAD by enhancing treatment monitoring over time.